Onderneming Vertex Pharmaceuticals Incorporated
Aandelen
VRTX
US92532F1003
Biotechnologie & Medisch Onderzoek
Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
418 USD | +0,17% | +0,55% | +2,73% |
Vakgebied
De netto-omzet is als volgt geografisch verdeeld: de Verenigde Staten (61,2%), Europa (31,5%) en overige (7,3%).
Aantal werknemers: 5 400
Verkoop per activiteit
USD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
Pharmaceutical
100,0
%
| 8 931 | 100,0 % | 9 869 | 100,0 % | +10,51% |
Verkoop per regio
USD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
United States
61,2
%
| 5 699 | 63,8 % | 6 040 | 61,2 % | +5,98% |
Europe
31,5
%
| 2 706 | 30,3 % | 3 109 | 31,5 % | +14,91% |
Other
7,3
%
| 526 | 5,9 % | 720 | 7,3 % | +36,87% |
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Chief Executive Officer | 51 | 01-02-17 | |
Jeffrey Leiden
CHM | Chairman | 68 | 08-07-09 |
Charles Wagner
DFI | Director of Finance/CFO | 55 | 10-04-19 |
Mike Tirozzi
CTO | Chief Tech/Sci/R&D Officer | - | 01-01-19 |
Carmen Bozic
CTO | Chief Tech/Sci/R&D Officer | 61 | 01-05-19 |
Stuart Arbuckle
COO | Chief Operating Officer | 58 | 04-09-12 |
Mark Bunnage
CTO | Chief Tech/Sci/R&D Officer | - | 01-01-16 |
Edward Atkinson
CTO | Chief Tech/Sci/R&D Officer | 58 | 01-07-20 |
David Altshuler
CTO | Chief Tech/Sci/R&D Officer | 59 | 01-01-15 |
Susie Lisa
IRC | Investor Relations Contact | - | 01-09-22 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Alan Garber
BRD | Director/Board Member | 68 | 08-06-17 |
Jeffrey Leiden
CHM | Chairman | 68 | 08-07-09 |
Bruce Sachs
BRD | Director/Board Member | 64 | 01-01-98 |
Director/Board Member | 69 | 17-05-11 | |
Lloyd Carney
BRD | Director/Board Member | 62 | 21-02-19 |
Michel Lagarde
BRD | Director/Board Member | 49 | 05-10-23 |
Sangeeta Bhatia
BRD | Director/Board Member | 55 | 18-06-15 |
Diana McKenzie
BRD | Director/Board Member | 59 | 03-06-20 |
Suketu Upadhyay
BRD | Director/Board Member | 55 | 18-05-22 |
Chief Executive Officer | 51 | 01-02-17 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 258 307 816 | 258 015 560 ( 99,89 %) | 0 | 99,89 % |
Bedrijfsgegevens
Sector
Verkoop per regio
Herzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
+2,73% | 108 mld. | |
+9,59% | 103 mld. | |
+6,58% | 23,48 mld. | |
-12,59% | 21,93 mld. | |
-3,29% | 19,68 mld. | |
-35,36% | 18,37 mld. | |
-13,29% | 16,33 mld. | |
+4,68% | 13,72 mld. | |
+34,25% | 12,15 mld. | |
-6,78% | 10,2 mld. |
- Beurs
- Aandelen
- Aandeel Vertex Pharmaceuticals Incorporated - Nasdaq
- Onderneming Vertex Pharmaceuticals Incorporated